Technical Analysis for VERV - Verve Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 2.05% | |
| Bollinger Band Squeeze | Range Contraction | 2.05% | |
| Lower Bollinger Band Walk | Weakness | 2.05% | |
| New 52 Week Low | Weakness | 2.05% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 2.05% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 8 hours ago |
| Down 2 % | about 8 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Up 3% | about 10 hours ago |
| Up 2% | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Verve Therapeutics, Inc. Description
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cardiovascular Disease Lipid Cholesterol Hypercholesterolemia Low Density Lipoprotein Pcsk9
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.04 |
| 52 Week Low | 4.585 |
| Average Volume | 1,404,164 |
| 200-Day Moving Average | 10.71 |
| 50-Day Moving Average | 5.70 |
| 20-Day Moving Average | 5.23 |
| 10-Day Moving Average | 5.09 |
| Average True Range | 0.33 |
| RSI (14) | 37.50 |
| ADX | 18.71 |
| +DI | 16.53 |
| -DI | 28.31 |
| Chandelier Exit (Long, 3 ATRs) | 4.79 |
| Chandelier Exit (Short, 3 ATRs) | 5.58 |
| Upper Bollinger Bands | 5.64 |
| Lower Bollinger Band | 4.82 |
| Percent B (%b) | 0.19 |
| BandWidth | 15.61 |
| MACD Line | -0.27 |
| MACD Signal Line | -0.29 |
| MACD Histogram | 0.0205 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.42 | ||||
| Resistance 3 (R3) | 5.40 | 5.22 | 5.35 | ||
| Resistance 2 (R2) | 5.22 | 5.11 | 5.24 | 5.32 | |
| Resistance 1 (R1) | 5.10 | 5.04 | 5.16 | 5.13 | 5.30 |
| Pivot Point | 4.93 | 4.93 | 4.96 | 4.94 | 4.93 |
| Support 1 (S1) | 4.81 | 4.82 | 4.87 | 4.83 | 4.66 |
| Support 2 (S2) | 4.63 | 4.75 | 4.65 | 4.64 | |
| Support 3 (S3) | 4.51 | 4.63 | 4.61 | ||
| Support 4 (S4) | 4.54 |
